In laboratory and preclinical studies, Retatrutide is investigated for its ability to activate interconnected endocrine signaling networks
Jastreboff AM et al., Phase 2 retatrutide, NEJM 2023 (NEJMoa2301972, PMID 37366315) -24,2% at 48 weeks at the 12 mg level
It demonstrates higher potency at the GIP receptor (EC50: 0.0643 nM) relative to the GLP-1 (EC50: 0.775 nM) and glucagon (EC50: 5.79 nM) receptors (Li et al., 2024)
Additionally, GLP-1 has been shown to enhance the proliferation and differentiation of endothelial progenitor cells through upregulation of VEGF, potentially promoting angiogenesis that could contribute to retinal complications [101,102]
The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney
Scheme 33